Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$498.25 USD
-6.91 (-1.37%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $498.28 +0.03 (0.01%) 5:12 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$498.25 USD
-6.91 (-1.37%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $498.28 +0.03 (0.01%) 5:12 PM ET
3-Hold of 5 3
A Value F Growth B Momentum C VGM
Zacks News
Here's Why Elevance Health (ELV) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Investors Should Retain Cigna (CI) Stock Now
by Zacks Equity Research
Cigna (CI) remains well-poised for growth on the back of continually growing premiums within its Cigna Healthcare unit. Solid cash-generating abilities also enable it to deploy capital.
Elevance (ELV) to Divest Life & Disability Business to StanCorp
by Zacks Equity Research
With the sale of the life and disability business, Elevance Health (ELV) is focusing on growing its more profitable operations.
ELV or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. DOCS: Which Stock Is the Better Value Option?
Elevance (ELV) Arm to Bring Virtual-First Plans to Georgia
by Zacks Equity Research
The cocktail of virtual and in-person options from Elevance Health's (ELV) part of the Anthem family of brands is expected to enrich members' health experience.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Here's Why You Should Retain Elevance (ELV) in Your Portfolio
by Zacks Equity Research
Strong local presence, improving top line, membership hike and significant new contracts in its government business poise Elevance Health (ELV) well for growth.
The Zacks Analyst Blog Highlights UnitedHealth, Elevance Health, Humana and Centene
by Zacks Equity Research
UnitedHealth, Elevance Health, Humana and Centene are included in this Analyst Blog.
Will Biden's Tax Hike Plan Extend Medicare's Life to 2050?
by Kaibalya Pravo Dey
U.S. President Joe Biden's proposal is also likely to enhance Medicare's ability to negotiate prices for drugs.
Select Medical (SEM) Q4 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
Select Medical (SEM) anticipates 2023 revenues to be within $6.5-$6.7 billion.
Why Is Elevance Health (ELV) Down 3.2% Since Last Earnings Report?
by Zacks Equity Research
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights JPMorgan Chase, Elevance Health, Vertex Pharmaceuticals, Sony Group and General Mills
by Zacks Equity Research
JPMorgan Chase, Elevance Health, Vertex Pharmaceuticals, Sony Group and General Mills are part of the Zacks top Analyst Blog.
Top Stock Reports for JPMorgan Chase, Elevance Health & Vertex Pharmaceuticals
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Elevance Health, Inc. (ELV) and Vertex Pharmaceuticals Incorporated (VRTX).
Why Elevance Health (ELV) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Pediatrix (MD) Q4 Earnings miss on High Operating Expenses
by Zacks Equity Research
Pediatrix (MD) anticipates 2023 adjusted EBITDA to be within $235-$245 million.
Centene (CNC) Q4 Earnings Miss on High Costs, '23 Premium View Up
by Zacks Equity Research
Centene's (CNC) fourth-quarter results suffer from elevated medical expenses, partly offset by growing premium and service revenues.
Cigna (CI) Q4 Earnings Top on U.S. Commercial Unit, Dividend Up
by Zacks Equity Research
Cigna's (CI) fourth-quarter results reflect the strong contribution from the Evernorth segment. Management sanctions a 10% increase in the quarterly dividend.
Humana (HUM) Q4 Earnings Beat Mark, '23 EPS View Upbeat
by Zacks Equity Research
Humana's (HUM) fourth-quarter results benefit from solid premiums from its individual Medicare Advantage business and the sound performance of the two newly formed segments.
Q4 Earnings Season Scorecard and Analyst Reports for Apple, Meta & Mastercard
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Meta Platforms, Inc. (META) and Mastercard Incorporated (MA).
HCA Healthcare (HCA) Q4 Earnings Lag on High Costs, Hikes Dividend
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter results suffer a blow from added expenses incurred due to Hurricane Ian. Increased patient admissions partly offset the downside.
Elevance Health (ELV) Tops on Q4 Earnings, Hikes Dividend
by Zacks Equity Research
Elevance Health's (ELV) fourth-quarter earnings gain on solid premiums from its Medicaid business. Management approves a quarterly dividend hike of 16%.
Elevance Health (ELV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Elevance Health (ELV) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Elevance Health (ELV) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 0.58% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Elevance Health (ELV) to Post Q4 Earnings: What to Expect
by Zacks Equity Research
Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums, Commercial & Specialty Business' sales and total expenses.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF